secwatch.observer — SEC 8-K summary
======================================

Issuer:     Perspective Therapeutics, Inc. (CATX)
CIK:        0000728387
Form:       8-K
Filed at:   2025-08-13T23:59:59+00:00
Accession:  0000950170-25-107609
Event type: earnings
Sentiment:  negative
Materiality: 0.60
Item codes: 2.02, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Perspective Therapeutics Q2 net loss $21.5M, EPS -$0.29; cash $192M; VMT-α-NET Cohort 3 opened
--------------------------------------------------------------------------------

- Net loss of $21.5M ($0.29 per share) vs $11.7M ($0.18) in Q2 2024; operating expenses rose 65%.
- Cash, cash equivalents & short-term investments $192M as of June 30, sufficient into late 2026.
- R&D expenses $16.6M (+79% YoY) driven by clinical site activities and drug product costs.
- FDA alignment obtained to open Cohort 3 (6.0 mCi) for [212Pb]VMT-α-NET; two patients dosed as of July 31.
- VMT01 melanoma program: combination with nivolumab cohort opened; five monotherapy patients treated.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/728387/000095017025107609/0000950170-25-107609-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/728387/000095017025107609/catx-20250813.htm
  HTML page:      https://secwatch.observer/filing/0000950170-25-107609

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer